Compositions for treating dry eye disease
The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
1. An eye drop suitable for topical application to an ocular surface comprising:
PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT at a concentration effective to reduce tear osmolarity upon topical application of the eye drop to the ocular surface so as to relieve dysfunction of a tear film or dry eye disease or symptoms associated therewith,
a polysorbate surfactant, and
one or more ophthalmically acceptable agents selected from the group consisting of a salt solution, a demulcent, an excipient, an astringent, a vasoconstrictor, and an emollient.
2. The eye drop of claim 1 , comprising PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT at a concentration of 10-10,000 μg/mL.
3. The eye drop of claim 1 , comprising PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT at a concentration of 50-500 μg/mL.
4. The eye drop of claim 1 , further comprising sodium hyaluronate or hyaluronic acid.
5. The eye drop of claim 4 , wherein the sodium hyaluronate or the hyaluronic acid is present at a concentration of 10-100,000 μg/mL.
6. The eye drop of claim 4 , wherein the sodium hyaluronate or the hyaluronic acid is present at a concentration of 500-5,000 μg/mL.
7. The eye drop of claim 1 , further comprising a surface active phospholipid selected from the group consisting of L-α-dipalmitoylphosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.
8. The eye drop of claim 7 , wherein the phospholipid is present at a concentration of 10-10,000 μg/mL.
9. The eye drop of claim 1 , wherein the salt solution comprises at least three different electrolytes selected from the group consisting of sodium phosphate, sodium chloride, potassium chloride, sodium bicarbonate, potassium bicarbonate, calcium chloride, magnesium chloride, sodium acetate, sodium citrate, hydrochloric acid, and sodium hydroxide.
10. The eye drop of claim 1 , wherein the PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT has an average molecular mass of between 50 kDa and 400 kDa.
11. The eye drop of claim 1 , wherein the PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT is a recombinant molecule.
12. The eye drop of claim 1 , wherein the PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT is a purified naturally occurring molecule.
13. The eye drop of claim 1 comprising PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT at a concentration of 10-500 μg/mL.
14. The eye drop of claim 1 comprising PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT at a concentration of 100-300 μg/mL.
15. The eye drop of claim 1 comprising PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT at a concentration of 100 μg/mL.
16. The eye drop of claim 1 comprising PRG4 or a lubricating fragment thereof comprising glycosylated repeats of the sequence KEPAPTT at a concentration of 200 μg/mL.